On-demand individualised digital therapy for children, teenagers and adults who stammer: product development and research studies

针对口吃儿童、青少年和成人的按需个性化数字治疗：产品开发和研究

• 批准号: 83002941
• 金额: $ 50.47万
• 依托单位: RESPIRA LTD
• 依托单位国家: 英国
• 项目类别: Innovation Loans
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=83002941
• 关键词: demand; individualised; digital; therapy; children

**Need**Stammering (or stuttering in US English) is a neurodevelopmental disorder, like dyslexia or autism, that starts in childhood and becomes chronic around 12 years of age. It affects 8% of children and 2% of teenagers and adults (BSA, 2022).**The main unmet needs are:*** No cost-effective ongoing/long-term (chronic) support: need for cost-effective support to self-manage chronic stammering (Ward, 2018).* No recognized "best practices" or "gold standard" exists for stammering treatment (Baxter et al., 2016),* Expensive therapy and lack of stammering speech therapy provision and training (Bercow, 2018).**Product Vision**Respira, a UK-based SME, has built a digital therapeutic platform called BeneTalk that can tackle all the above-mentioned unmet needs and address societal inequalities, by building a speech therapy solution for stammering that is:1. Accessible to everyone (current development): on-demand support to self-manage chronic stammering without professional support intervention.2. Effective for everyone (this project): delivering a highly personalised digital speech therapy.**Project opportunity**Although there are no standard care options for stammering (i.e., no gold standard), the scientific community agrees that stammering treatment has to be highly individualised (Baxter 2016, Manning & DiLollo, 2017). It is therefore the motivation of this project to build a highly individualised therapy solution for PWS, enabling BeneTalk to be the first evidence-based Digital Therapeutics (DTx) solution for stammering.**Disruptive approach**A previous InnovateUK grant (Ref: 72343) enabled Respira to de-risk and build in-house expertise by developing BeneTalk. Top innovations vs existing technological solutions are:1\. Real-time Feedback: Visual, audio or haptic feedback in real-time to learn to modify speech patterns and behaviours.2\. Speech Tracking: Learning and practice at any speaking opportunity (outside the clinic or/and practice environment).3\. Use of machine learning to improve therapy outcomes: leveraging gathered data from a global user base (this project).4\. Community-Based Rehabilitation: Community speech practice & peer support.BeneTalk 2.0 was launched with premium features in the UK and U.S., and started generating revue with as a solution 5 to 10x cheaper and more effective than existing solutions.**Outputs**The primary objective of this project is to make further technical improvements into BeneTalk to make it more commercially viable, by integrating individualised therapy for all ages. The main project outputs are (within the "availability period"):1. Prototyping and testing individualised therapeutics solutions.2. Validating the new solution with patients, by improving the quality of life of the users and their families (particularly parents).

**需要** 口吃（或美式英语中的口吃）是一种神经发育障碍，如阅读障碍或自闭症，从童年开始，在 12 岁左右变成慢性病。它影响 8% 的儿童和 2% 的青少年和成人（BSA，2022）。**主要未满足的需求是：*** 没有具有成本效益的持续/长期（慢性）支持：需要具有成本效益的支持自我管理慢性口吃（Ward，2018）。*口吃治疗不存在公认的“最佳实践”或“黄金标准”（Baxter 等人，2016），*昂贵的治疗费用以及缺乏口吃言语治疗的提供和培训（Bercow，2018）。**产品愿景**Respira 是一家总部位于英国的中小企业，它建立了一个名为 BeneTalk 的数字治疗平台，可以解决所有上述未满足的需求和通过构建针对口吃的言语治疗解决方案来解决社会不平等问题：1。每个人都可以使用（当前开发）：按需支持自我管理慢性口吃，无需专业支持干预。2。对每个人都有效（该项目）：提供高度个性化的数字言语治疗。**项目机会**尽管口吃没有标准的护理选择（即没有黄金标准），但科学界一致认为口吃治疗必须高度个性化（Baxter 2016，Manning & DiLollo，2017）。因此，该项目的动机是为 PWS 构建高度个性化的治疗解决方案，使 BeneTalk 成为首个基于证据的口吃数字治疗 (DTx) 解决方案。**颠覆性方法**之前的 InnovateUK 资助（参考号：72343） ）使 Respira 通过开发 BeneTalk 来降低风险并建立内部专业知识。与现有技术解决方案相比，顶级创新是：1\。实时反馈：实时视觉、音频或触觉反馈，以学习修改言语模式和行为。2\。言语跟踪：在任何言语机会（诊所或/和练习环境之外）进行学习和练习。3\。使用机器学习来改善治疗结果：利用从全球用户群收集的数据（本项目）。4\。基于社区的康复：社区演讲练习和同伴支持。BeneTalk 2.0 在英国和美国推出，具有高级功能，并开始产生评论，作为一种比现有解决方案便宜 5 到 10 倍、更有效的解决方案。**输出**该项目的主要目标是通过整合适合所有年龄段的个体化治疗，对 BeneTalk 进行进一步的技术改进，使其更具商业可行性。主要项目产出为（“可用期限”内）： 1．原型设计和测试个性化治疗解决方案。2。通过改善用户及其家人（特别是父母）的生活质量，与患者一起验证新的解决方案。